[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625230":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":10,"centralContacts":68,"locations":78,"responsibleParty":95,"collaborators":10,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":101,"sex":107,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":10,"studyType":113,"phases":10,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":81,"whyStopped":10,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Fujian Medical University","OTHER",[8,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Neoadjuvant Treatment Group",null,"Participants will undergo neoadjuvant treatment with multikinase inhibitors (mTKIs), specific receptor inhibitors (including RET inhibitors or BRAF ± MEK inhibitors), or combination regimens containing a PD-1 inhibitor. All regimens will be administered for at least two cycles prior to surgery.",[13,14,15,16,17,18],"Drug: Multitarget Tyrosine Kinase Inhibitors","Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib","Drug: RET Inhibitor","Drug: PD(L)-1 inhibitor","Procedure: Biopsy","Procedure: Surgery",{"label":20,"type":10,"description":21,"interventionNames":22},"Upfront Surgery Group","The participants in this group will undergo radical surgery directly after the diagnosis of LATC, based on MDT consensus and patient's preference.",[17,18],[24,32,39,46,53,61,65],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Multitarget Tyrosine Kinase Inhibitors","Patients with or without actionable genomic alterations may receive a multikinase inhibitor (e.g., lenvatinib or anlotinib) as neoadjuvant therapy.",[9],[30,31],"Lenvatinib","Anlotinib",{"type":25,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"BRAF inhibitor dabrafenib and MEK inhibitor trametinib","Patients with BRAF V600E mutation may receive combination therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.",[9],[37,38],"Dabrafenib","Trametinib",{"type":25,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"RET Inhibitor","Patients with RET fusion may receive a selective RET inhibitor (e.g., selpercatinib).",[9],[44,45],"Selpercatinib","Pralsetinib",{"type":25,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"PD(L)-1 inhibitor","In selected cases, combination regimens incorporating immunotherapy may be considered.",[9],[51,52],"Pembrolizumab","Nivolumab",{"type":54,"name":55,"description":56,"armGroupLabels":57,"otherNames":58},"PROCEDURE","Biopsy","While fine-needle aspiration (FNA) is the standard initial diagnostic modality for thyroid nodules, core needle biopsy (CNB) is performed to obtain tissue cores for histological subtyping and molecular profiling in locally advanced cases.",[9,20],[59,60],"Core Needle Biopsy","Fine-needle Aspiration",{"type":54,"name":62,"description":63,"armGroupLabels":64,"otherNames":10},"Surgery","Patients considered resectable after neoadjuvant therapy will undergo definitive surgery, as determined by consensus of the multidisciplinary team (MDT).",[9],{"type":54,"name":62,"description":66,"armGroupLabels":67,"otherNames":10},"Patients deemed resectable at baseline will undergo immediate surgery based on MDT consensus and informed patient preference.",[20],[69,74],{"name":70,"role":71,"phone":72,"phoneExt":10,"email":73},"Wenxin Zhao, M.D., Ph.D.","CONTACT","+86-591-86218065","fzhzwx6688@163.com",{"name":75,"role":71,"phone":76,"phoneExt":10,"email":77},"Zihan Tang, M.D.","+86-13615083322","tzhan2016@163.com",[79],{"facility":80,"status":81,"city":82,"state":83,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"Fujian Medical University Union Hospital","RECRUITING","Fuzhou","Fujian","350001","China","CN",{"type":88,"coordinates":89},"Point",[90,91],119.30611,26.06139,{"lat":91,"lon":90},[94],{"name":70,"role":71,"phone":72,"phoneExt":10,"email":73},{"type":96,"investigatorFullName":97,"investigatorTitle":98,"investigatorAffiliation":80,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","wenxin zhao","Professor and Chief Surgeon, Department of Thyroid Surgery","100625230","response-to-neoadjuvant-treatment-in-locally-advanced-thyroid-cancer-100625230",false,"NCT07419932","Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","Biochemical, Radiological and Pathological Responses to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: A Multicenter Study","NeoLATC","Inclusion Criteria:\n\n* Age ≥ 14 years at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Histologically or cytologically confirmed thyroid carcinoma, including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC).\n* LATC defined as clinical stage T4N0-1 at baseline, as confirmed by a multidisciplinary thyroid oncology board.\n* For patients with distant metastasis, the potential benefit from surgical intervention must be documented by the treating team.\n* Presence of at least one measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Normal function of major organs.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Patients who refuse tumor tissue biopsy or surgery.\n* Prior thyroid or major neck surgery.\n* History of other treatments for cancer, including surgery, chemotherapy, radiotherapy, or molecular targeted therapy, that may affect the current treatment plan.\n* Concurrent active malignancies.\n* Uncontrolled systemic diseases, including diabetes, hypertension, etc.\n* Pregnancy or breastfeeding.","ALL","14 Years","80 Years",{"count":111,"type":112},120,"ESTIMATED","OBSERVATIONAL","This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.",[116,117],"Thyroid Cancer","Thyroid Neoplasms",[116,119,120],"locally advanced","Neoadjuvant Therapy","2026-02-12",{"date":123,"type":124},"2026-02-19","ACTUAL",{"date":126,"type":124},"2025-12-23",{"date":128,"type":112},"2029-06-30",{"name":5,"class":6},1]